Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?
The Journal of Allergy and Clinical Immunology: In Practice · 2023
DOI: 10.1016/j.jaip.2023.01.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Andrea Portacci und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy. Electronic address: …. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Defining super-response to biologic treatment is a major concern in severe asthma. Although many definitions have been proposed, there is still a gap between the clinical perception of the super-response and a standardized classification. The current definition of super-response mainly relies on several clinical features, while many aspects of severe asthma inflammation and lung function are still poorly considered. Furthermore, many criteria of severe asthma super-response overlap with those of the clinical remission, leaving room for possible misclassifications. In this context, identifying the correct trajectory linking these 2 aspects of type 2-high severe asthma could help clinicians to understand which factors can predict a greater response to biologic therapies. In this paper, we review various aspects of super-response assessment, proposing some new criteria for its definition as well as new perspectives on its relationship with severe asthma clinical remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy. Electronic address: a.portacci01@gmail.com.
- Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.
Zitieren
APA
Portacci, A., Dragonieri, S., & Carpagnano, G. E. (2023). Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.01.021
Vancouver
Portacci A, Dragonieri S, Carpagnano GE. Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.01.021
BibTeX
@article{Portacci2023,
author = {Portacci, Andrea and Dragonieri, Silvano and Carpagnano, Giovanna Elisiana},
title = {Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
doi = {10.1016/j.jaip.2023.01.021}
}
EUVIMED